Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

The Cesarean Study: Optimizing Cesarean Sections and Improving Patient-Healthcare Provider Trust Using Evidence Informed Recommendations (CS)

6 augusti 2026 uppdaterad av: Lund University

The Cesarean Study

Cesarean section (CS) rates have rapidly increased worldwide, with projections suggesting that by 2030, one in every three births will be by CS (1). In Sweden, rates have more than doubled from 9% in the 1990s, to 20% in 2024 (2). While CS can be a life-saving procedure when medically indicated, non-essential CS increase the risk of complications and have been linked to increased maternal morbidity and even death, neonatal respiratory issues, and longer recovery times (3). They also place added strain on already burdened healthcare systems by increasing the use of medical resources and staff capacity.

The purpose of this project is to evaluate the use of the "Cesarean Bundle", a three-part intervention designed to improve patient-clinician communication and trust.

Primary Aim: To evaluate the impact of the "Cesarean Bundle" in improving patient-clinician communication and trust compared to standard care.

Hypothesis: Use of the "Cesarean Bundle" will improve patients' trust in their healthcare providers.

Secondary Aim: To evaluate whether adoption of the "Cesarean Bundle" is associated with changes in cesarean section rates, especially among low-risk obstetric populations.

Hypothesis: Implementation of the "Cesarean Bundle" will be associated with a reduction in overall cesarean section rates, particularly among low-risk pregnancies.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Rising CS rates globally and across Europe pose a growing challenge to maternal-newborn health (1). In some European countries, CS rates have soared to 55%, and in Sweden, almost 20,000 procedures are performed annually, with numbers continuing to rise (2, 3). Strikingly, nearly 40% of these are planned cesareans, highlighting a critical need to change on-going clinical practices, especially for low-risk pregnancies, which are well-known drivers of CS rates (5, 6). These rates also contradict the World Health Organization's (WHOs) recommendations that CS rates above 10-15% are not associated with improved maternal-newborn outcomes (5). The WHO has provided clear guidance for reducing non-essential CS (5, 6), emphasizing evidence-based strategies such as requiring a second clinician's sign-off and fostering multidisciplinary reflection, both of which are key parts of the Cesarean study's intervention.

Qualitative evidence from Kingdon et al. (7,8) has shown that women want their birth preferences acknowledged, value individualized information, and are influenced by how health professionals communicate, making shared decision-making essential. However, studies from Quebec (9) and Spain (10) revealed that there are some persistent barriers to implementing guidelines, such as fragmented care and inconsistent messaging, which reinforce the well-known "know-do gap" where best practices fail to reach routine care. The Cesarean Study responds directly to this need, testing a three-part therapy bundle aligned with WHOs recommendations for maximal impact.

Population Pregnant women remitted to clinicians for planned CS discussion.

Intervention

The "Cesarean Bundle", a three-part, decision-support model, comprising of:

I. The Cesarean Discussion Guide, which is a structured clinical tool designed to facilitate personalized, evidence-based conversations between clinicians and patients considering planned cesarean birth. It captures key clinical data, patient values, and birth preferences, integrates risk stratification using the Robson Classification (11-13), and presents short- and long-term outcomes of cesarean versus vaginal birth in a clear, visual format. By standardizing counseling and embedding shared decision-making into routine care, the guide supports more equitable, informed, and patient-centered birth planning. The principal investigator (MZ) has developed the guide with support from Ariadne Labs, Boston USA.

II. Mandatory second opinion/team decision from another clinician for all planned cesarean requests; and, III. Regular team audits reviewing decision-making patterns.

Standard care, consisting of usual clinical consultations for discussing and approving planned CS, without structured guidance or required secondary clinician or team review.

Outcomes Primary outcome Patient-reported trust in the care team, measured by the Health Care Relationship Trust Scale-Revised (HCRTS-R) (14)

Secondary outcomes i) Change in planned CS rate before and after intervention, including subdivisions by Robson Groups for risk stratification ii) Composite of severe neonatal outcomes, including perinatal mortality, 5-min Apgar score <6, hypoxic ischemic encephalopathy grade II-III, intracranial hemorrhage, neonatal seizures, neonatal infection, hypoglycemia, respiratory distress, umbilical arterial pH< 7.05 iii) Composite of severe maternal outcomes, including postpartum hemorrhage (>1000ml), ICU admission, postpartum infection iv) Twelve question survey for clinicians and patients reporting experience of usability, acceptability, feasibility of intervention vs standard care v) Qualitative interviews using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, and Maintenance) (15) to evaluate the impact and real-world applicability of the Cesarean Bundle across patient, partner, clinician, and system levels vi) Cost-analysis of intervention vs standard care.

Studietyp

Interventionell

Inskrivning (Beräknad)

260

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

  • Pregnant women aged ≥18 years
  • Referred for consultation regarding planned cesarean section
  • Able to provide informed consent (with interpreter support if needed)

Exclusion Criteria:

  • Women with an absolute medical indication for cesarean section (e.g., placenta previa), where shared decision-making is not applicable
  • Women who decline participation in the study components (e.g., surveys/interviews)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Intervention: Cesarean Bundle
Cesarean Bundle (structured discussion guide, mandatory second/team opinion, and regular team reviews/audits)

The Cesarean Bundle is a structured, three-component clinical intervention designed to support evidence-based and shared decision-making for planned cesarean sections:

  1. Cesarean Discussion Guide:

    A standardized decision-support tool used during all consultations for planned cesarean section. It incorporates clinical data, risk stratification (e.g., Robson classification), and clear information on short- and long-term risks and benefits of cesarean versus vaginal birth, while also capturing patient preferences and values.

  2. Mandatory Second/team Opinion:

    All requests for planned cesarean section require review and approval by a second clinician/team before a final decision is made.

  3. Regularl Multidisciplinary Team Meetings:

Regular team-based reviews of cases and decision-making patterns to promote consistency, reflection, and adherence to evidence-based practice.

The intervention is integrated into routine care, with minimal disruption to standard workflows, and is support

Inget ingripande: Control Arm
Standard care (usual clinical practice without structured tools)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient-Reported Trust in the Care Team
Tidsram: Pilot: 12-18 months; Actual study 48 months
Patient-Reported Trust in the Care Team Measured using the Health Care Relationship Trust Scale-Revised (HCRTS-R), a validated questionnaire assessing patients' trust in their healthcare providers following consultation for planned cesarean section. Each of the survey's 13 items is scored individually on a five-point scale (0 to 4), where the item score reflects the patient's immediate assessment of specific relational experiences, such as active listening, truth-telling, and respect for privacy. After converting one reverse-worded question to ensure that higher numbers consistently reflect stronger alignment with positive relational attributes, the individual item scores are summed to generate a cumulative total score ranging from 0 to 52. Within this spectrum, the higher the score, the better the reported trust and communication.
Pilot: 12-18 months; Actual study 48 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Cesarean section rates
Tidsram: Pilot: 12-18 months. Actual study: 48-54 months as some cesarean section may be reported at later date after the pregnancy has led to the birth of the baby.
Using Robson Groups
Pilot: 12-18 months. Actual study: 48-54 months as some cesarean section may be reported at later date after the pregnancy has led to the birth of the baby.
Maternal outcome
Tidsram: Pilot: 12-18 months. Main study: 48-54 months as some maternal outcomes may be reported at later date after the pregnancy has led to the birth of the baby.
This is a composite of whether any of the following maternal outcomes was found (Y/N): postpartum hemorrhage (> or = 1000 ml), admission to intensive care unit (ICU) admission, and postpartum infection needing antiobiotics.
Pilot: 12-18 months. Main study: 48-54 months as some maternal outcomes may be reported at later date after the pregnancy has led to the birth of the baby.
Neonatal outcome
Tidsram: Pilot: 12-18 months. Actual study: 48-54 months depending on when data is available from the patient charts and once the pregnancy has led to birth of the baby
This is a composite of whether any of the following neonatal outcomes was present (Y/N): perinatal mortality, 5-minute Apgar score less than 7, hypoxic-ischemic encephalopathy (grade I-III), intracranial hemorrhage, neonatal seizures, infection, hypoglycemia, respiratory distress, and umbilical artery pH <7.05.
Pilot: 12-18 months. Actual study: 48-54 months depending on when data is available from the patient charts and once the pregnancy has led to birth of the baby
Patient-Reported Experience
Tidsram: Pilot 12-18 months. Actual study 48-54 months
This is a survey that uses a 12-item questionnaire assessing acceptability, usability, and feasibility of the intervention. Total score 0-12 where 12 is the highest number and indicated best reported experience.
Pilot 12-18 months. Actual study 48-54 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 maj 2026

Primärt slutförande (Beräknad)

15 maj 2030

Avslutad studie (Beräknad)

31 december 2035

Studieregistreringsdatum

Först inskickad

26 juni 2026

Först inskickad som uppfyllde QC-kriterierna

6 augusti 2026

Första postat (Faktisk)

12 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 augusti 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified individual participant data (IPD) will be shared, including demographic variables (e.g., age, parity, BMI), clinical characteristics (e.g., pregnancy and delivery data, indication for cesarean section), intervention exposure, and outcome measures (e.g., planned cesarean rates, maternal and neonatal outcomes, and patient-reported trust scores).

Survey responses (e.g., HCRTS-R and acceptability/feasibility questionnaires) and relevant implementation metrics may also be included. All data will be pseudonymized, with direct identifiers removed, in accordance with GDPR and applicable data protection regulations.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera